UNSPSC 51183605: Glucagon hydrochloride

This classification denotes a therapeutic hormone, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1H87NVF4DB. European Medicines Agency schedules Glucagon hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02349MIG. Glucagon hydrochloride generally arises in the molecular formula C153H225N43O49S.CLH. The term 'glucagon hydrochloride' is a U.S. FDA Orange Book designation. Most nations, for tariff and trade purposes, schedule glucagon hydrochloride under HS 29371900 and SITC 54154.

Glucagon hydrochloride bears US NLM identifiers UMLS ID C0795614 and NCI Concept Code C87236. SMILES: As of Q4 2014, GLUCAGON HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

UNSPSC 51183605 Glucagon hydrochloride is a Commodity code covering pharmaceutical products supplied to state and local government health facilities and agencies. State and local governments procure glucagon and similar injectable emergency medications primarily through cooperative purchasing agreements that consolidate demand across multiple jurisdictions and establish standing contracts with manufacturers and pharmaceutical wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which administers multi-state purchasing on behalf of member states including Minnesota and Oregon, represents the primary recent issuing body soliciting under this code. Buyers include state health departments, public hospitals, emergency services agencies, and local government medical facilities that maintain glucagon in emergency kits and acute-care settings. The pharmaceutical supply chain in state and local procurement flows through authorized wholesale distributors—in MMCAP's current solicitation, AmerisourceBergen (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—who handle logistics and inventory management on behalf of end-user agencies.

MMCAP's January 2026 RFP for Generic Multi Source Pharmaceuticals and OTC Products (Solicitation Number S1070000015802, due March 26, 2026) demonstrates current activity under this code. Manufacturers must supply products with precise National Drug Codes (NDC), maintain cGMP and Drug Supply Chain Security Act (DSCSA) compliance, carry insurance including $5,000,000 commercial general liability, and agree to a 3 percent administrative fee on all contract purchases. The award, effective July 1, 2026, will establish multiple vendor contracts for a two-year initial term with optional extensions through June 30, 2028. Evaluation weights price competitiveness at 75 percent, with remaining points distributed across fixed pricing, EDI capability, administrative compliance, and fee acceptance. This cooperative purchasing model concentrates significant procurement activity across multiple states and local jurisdictions, though the source does not disclose specific budget ranges or award values for the overall contract or individual product lines like glucagon.